MQS Management LLC Takes $450,000 Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

MQS Management LLC bought a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 710 shares of the biopharmaceutical company’s stock, valued at approximately $450,000.

A number of other institutional investors and hedge funds have also made changes to their positions in REGN. Capital International Investors boosted its stake in shares of Regeneron Pharmaceuticals by 41.6% during the 4th quarter. Capital International Investors now owns 4,736,929 shares of the biopharmaceutical company’s stock worth $3,373,859,000 after purchasing an additional 1,390,534 shares during the last quarter. Geode Capital Management LLC lifted its holdings in Regeneron Pharmaceuticals by 6.8% in the 4th quarter. Geode Capital Management LLC now owns 2,427,630 shares of the biopharmaceutical company’s stock worth $1,726,940,000 after buying an additional 155,369 shares in the last quarter. Dodge & Cox grew its stake in Regeneron Pharmaceuticals by 0.4% during the 4th quarter. Dodge & Cox now owns 2,321,316 shares of the biopharmaceutical company’s stock valued at $1,653,543,000 after purchasing an additional 9,381 shares in the last quarter. Price T Rowe Associates Inc. MD raised its holdings in Regeneron Pharmaceuticals by 63.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 2,085,447 shares of the biopharmaceutical company’s stock valued at $1,485,527,000 after acquiring an additional 810,144 shares in the last quarter. Finally, Franklin Resources Inc. increased its holdings in Regeneron Pharmaceuticals by 7.9% in the fourth quarter. Franklin Resources Inc. now owns 2,045,210 shares of the biopharmaceutical company’s stock valued at $1,456,864,000 after buying an additional 149,124 shares during the last quarter. 83.31% of the stock is owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Trading Up 1.4%

Shares of REGN opened at $567.74 on Monday. The stock has a market capitalization of $61.30 billion, a P/E ratio of 14.45, a PEG ratio of 2.11 and a beta of 0.33. Regeneron Pharmaceuticals, Inc. has a twelve month low of $476.49 and a twelve month high of $1,211.20. The company has a quick ratio of 4.03, a current ratio of 4.93 and a debt-to-equity ratio of 0.09. The firm has a fifty day simple moving average of $545.22 and a two-hundred day simple moving average of $619.17.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share for the quarter, missing analysts’ consensus estimates of $8.83 by ($0.61). The business had revenue of $3.03 billion during the quarter, compared to the consensus estimate of $3.40 billion. Regeneron Pharmaceuticals had a return on equity of 15.27% and a net margin of 31.94%. Regeneron Pharmaceuticals’s quarterly revenue was down 3.7% compared to the same quarter last year. During the same quarter in the prior year, the business posted $9.55 earnings per share. On average, research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, June 6th. Investors of record on Tuesday, May 20th were given a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a dividend yield of 0.62%. The ex-dividend date of this dividend was Tuesday, May 20th. Regeneron Pharmaceuticals’s dividend payout ratio is currently 8.96%.

Analyst Upgrades and Downgrades

Several research firms have commented on REGN. Citigroup decreased their target price on shares of Regeneron Pharmaceuticals from $700.00 to $650.00 and set a “buy” rating for the company in a research report on Monday, June 2nd. Wall Street Zen lowered shares of Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, May 1st. Argus lowered shares of Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Monday, June 30th. BMO Capital Markets lowered their price target on Regeneron Pharmaceuticals from $800.00 to $600.00 and set an “outperform” rating for the company in a research note on Monday, June 2nd. Finally, Guggenheim reissued a “buy” rating on shares of Regeneron Pharmaceuticals in a research report on Friday, May 30th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating, sixteen have assigned a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $823.54.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.